‣ For inclusion in the study, patients should fulfill the following criteria:

• Female.

• Aged at least 15 years at the time of screening.

• Body weight \> 35 kg.

• Histologically documented FIGO 2018 Stage IIIA to IVA cervical adenocarcinoma, cervical squamous carcinoma, or cervical adenosquamous carcinoma, with no evidence of metastatic disease.

• Initial staging procedures performed no more than 42 days prior to the first dose of CCRT.

• Provision of FFPE tumor sample to assess the PD-L1 expression.

• Must not have progressed following CCRT, participants with persistent disease after definitive CCRT must not be amenable to other available therapies with curative intent.

• WHO/ECOG performance status of 0 or 1.

• Adequate organ and bone marrow function.

⁃ Capable of providing signed informed consent.